All articles — 4121 total
ELAN reported Q1 2026 results on May 6 that landed well ahead of consensus, and the stock's response has put short sellers firmly on the back foot. Adjusted EPS came in at $0.40 against a $0.35 estimate. Sales hit…
PDD Holdings enters its May 19 earnings window with the options market unusually relaxed — while short positioning has been quietly drifting higher over the past month, the lending market remains well-supplied and…
Liquidia Corporation heads into its May 11 Q1 results with a striking divergence: the CEO and CFO have been selling aggressively near current prices, while short sellers have been quietly covering throughout April and…
DAVA heads into its May 18 Q3 results with options traders making a speculative bet on a bounce — even as the stock trades near multi-year lows and every recent analyst move has been a cut. The most notable development…
Establishment Labs has climbed 10% in a week and 22% in a month — and its founder has been selling into every uptick. The most striking story this week is the insider tape. Juan José Chacón Quirós, the company's…
KKR & Co. Inc. heads into its May 8 earnings call with a striking contrast at the heart of the investment case: the firm's own co-CEOs bought shares aggressively during the February sell-off, while the Street has spent…
BV reported Q2 fiscal 2026 results on May 5th — and the print was a split verdict. Revenue topped estimates and full-year guidance moved higher, but EPS came in light. That combination explains the week: the stock…
CNS Pharmaceuticals has become one of the most charged short-selling situations in the small-cap biotech universe this week, with a violent price surge colliding head-on with a rapidly building short position and a…
Equitable Holdings closed the week at $44.04, up 5.3% over five days and 16.5% over the past month. The catalyst was a Q1 earnings beat that sent the stock 4.4% higher in a single session — and immediately pulled in a…
TALO just reported Q1 2026 results, and on the surface they look solid. Adjusted EPS came in at -$0.07, well ahead of the -$0.18 consensus estimate. Revenue hit $472M against a $433M forecast. The stock's response,…
EverQuote delivered one of the more violent single-session moves in US small-cap markets this week — a 64% jump on May 5 after its Q1 earnings print, leaving the stock at $23.82 and up nearly 47% on the week. The real…
AVGO has done something remarkable over the past month: it has gained 36% while the broader semiconductor complex has been grappling with tariff noise and macro uncertainty. The stock closed at $427.36 on Tuesday, up…
Hamilton Insurance Group enters the week down 6.5% — the biggest talking point for the stock right now is the gap between that price drop and an analyst community that just raised targets. The Street's reaction to Q1…
GRAL enters the post-earnings week in an interesting position: the stock beat Q1 estimates, absorbed a 2.3% single-day pullback, and yet short sellers barely flinched — leaving a meaningful short position intact…
Viemed Healthcare walked into its Q1 2026 earnings print carrying a 3.5% weekly loss and walked out with a 2.3% bounce — a tidy illustration of how much was already priced for caution before the numbers dropped. Q1…
GD Culture Group enters its May 15 earnings with a remarkable price run at its back — and short sellers quietly stepping aside. The stock has doubled over the past month, closing at $5.99 on May 5. That +22% single-day…
Hyperion DeFi heads into its May 11 earnings report with a fresh equity raise landing squarely on top of a 44% one-month rally and a short base that has halved since April. The timing of the capital raise is the…
One Stop Systems just put its best quarterly beat on record — and the stock still has active shorts building positions heading into the reaction. Q1 2026 adj. EPS of $0.01 crushed the $(0.04) consensus estimate.…
Red Violet just delivered the clearest signal it has given investors all year — a Q1 earnings beat that landed after the close on May 6, with the stock already up 6% on the week heading into the print. The numbers were…
InflaRx enters its May 7 results carrying a month-long price surge and a borrow market that has quietly loosened — a setup that puts the clinical pipeline firmly in the spotlight. The stock's 116% one-month gain to…
